Latest Strategic Partnerships News

Opthea has successfully settled its Development Funding Agreement, avoiding a potential $680 million liability and securing $20 million in cash. Leadership changes include the CEO and CFO stepping down, with the Chairman assuming CEO duties.

HUB24 Limited reported robust FY25 results, driven by a 34% surge in platform funds under administration and a 44% rise in underlying net profit after tax. The company expanded its adviser base and boosted dividends, reinforcing its leadership in Australia's wealth management technology sector.

Amplitude Energy has delivered record production and earnings in FY25, driven by operational improvements and a strategic joint venture for the East Coast Supply Project.

Amplitude Energy Limited reported a 22% revenue increase to A$268.1 million for FY25, narrowing its net loss significantly while progressing its East Coast Supply Project with a new joint venture partner.

Challenger has reported a robust FY25 performance, with normalised net profit after tax rising 9% to $456 million and return on equity exceeding targets. The company’s strategic focus on annuities and digital transformation positions it well for continued growth in FY26.

Challenger Limited reported a 9% increase in normalised net profit after tax for FY25, driven by strong Life business cash earnings and resilient Funds Management performance despite net outflows. The company also announced an 11% dividend increase and provided positive FY26 EPS guidance amid ongoing regulatory reforms.

Challenger Limited reported a robust FY25 with a 9% rise in normalised profit and a strategic push into digital transformation and retirement income solutions.

Challenger Limited celebrates four decades with a robust 9% rise in net profit and a strategic digital transformation, positioning itself at the forefront of Australia’s retirement income market.

Rhythm Biosciences has launched a $3.75 million placement alongside an offer of over 52 million new options, all contingent on shareholder approval. The move aims to bolster working capital as the company advances its cancer diagnostic products.

Mount Burgess Mining has acquired two promising gold projects in Western Australia, Viking and Blair North, with plans to commence drilling in late 2025. The acquisitions come with strong historical drill results and a $900,000 capital raise to fund exploration.

ReNerve Limited has achieved a key milestone with its first sale and clinical use of a deep dermal tissue product in the US, broadening its surgical applications beyond nerve repair. This move complements its existing nerve repair portfolio and sets the stage for further product launches later this year.

Rhythm Biosciences has announced a $3.75 million placement to accelerate the commercial launch of its ColoSTAT® cancer detection test and expand its geneType™ product suite into key markets. The capital raise includes director participation and attaching options, pending shareholder approval.